Marshall Wace, LLP Larimar Therapeutics, Inc. Transaction History
Marshall Wace, LLP
- $72.2 Billion
- Q2 2024
A detailed history of Marshall Wace, LLP transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 95,214 shares of LRMR stock, worth $633,173. This represents 0.0% of its overall portfolio holdings.
Number of Shares
95,214
Previous 99,788
4.58%
Holding current value
$633,173
Previous $757,000
8.85%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding LRMR
# of Institutions
112Shares Held
68.1MCall Options Held
290KPut Options Held
38.9K-
Deerfield Management Company, L.P. (Series C) New York, NY21.2MShares$141 Million3.23% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$40.2 Million0.66% of portfolio
-
Janus Henderson Group PLC London, X04.38MShares$29.1 Million0.02% of portfolio
-
Goldman Sachs Group Inc New York, NY4.33MShares$28.8 Million0.01% of portfolio
-
Blue Owl Capital Holdings LP New York, NY3.86MShares$25.7 Million11.62% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $288M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...